The effects in the combination group were driven by the Akt/GSK-3β/β-catenin signaling pathway, and deregulation of β-catenin expression was predictive of poor outcome in ccRCC patients. The gene discussed is AKT1; the disease is nonpapillary renal cell carcinoma.